Loading...
Market
What will be FILSPARI's market share in the IgAN treatment market by March 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Sales reports and market analysis reports
Story
Travere's FILSPARI for IgAN Wins FDA Approval, Stock Up 5.7%
Sep 6, 2024, 04:39 AM
Travere Therapeutics has announced that its drug FILSPARI (sparsentan) has received full approval from the FDA for treating IgA nephropathy (IgAN). FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgAN. Following the approval, Travere Therapeutics' stock (TVTX) saw a pre-market gain of 5.7%.
View original story
Similar markets
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Novartis • 25%
Calliditas • 25%
Ligand Partner • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%